222 related articles for article (PubMed ID: 20202461)
1. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.
Mauri D; Valachis A; Polyzos NP; Tsali L; Mavroudis D; Georgoulias V; Casazza G
J Natl Compr Canc Netw; 2010 Mar; 8(3):279-86. PubMed ID: 20202461
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
Yan T; Yin W; Zhou Q; Zhou L; Jiang Y; Du Y; Shao Z; Lu J
Eur J Cancer; 2012 Jan; 48(2):187-95. PubMed ID: 22100904
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2015 Oct; 386(10001):1353-1361. PubMed ID: 26211824
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
7. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis.
Valachis A; Polyzos NP; Georgoulias V; Mavroudis D; Mauri D
Gynecol Oncol; 2010 Apr; 117(1):139-45. PubMed ID: 20061004
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
Costa L
Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
[TBL] [Abstract][Full Text] [Related]
12. Role of Bisphosphonates in Breast Cancer Therapy.
Goldvaser H; Amir E
Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefits of bone targeted agents in early breast cancer.
Coleman R
Breast; 2019 Nov; 48 Suppl 1():S92-S96. PubMed ID: 31839171
[TBL] [Abstract][Full Text] [Related]
15. Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.
Kroep JR; Charehbili A; Coleman RE; Aft RL; Hasegawa Y; Winter MC; Weilbaecher K; Akazawa K; Hinsley S; Putter H; Liefers GJ; Nortier JWR; Kohno N
Eur J Cancer; 2016 Feb; 54():57-63. PubMed ID: 26722766
[TBL] [Abstract][Full Text] [Related]
16. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
18. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
Eisen A; Somerfield MR; Accordino MK; Blanchette PS; Clemons MJ; Dhesy-Thind S; Dillmon MS; D'Oronzo S; Fletcher GG; Frank ES; Hallmeyer S; Makhoul I; Moy B; Thawer A; Wu JY; Van Poznak CH
J Clin Oncol; 2022 Mar; 40(7):787-800. PubMed ID: 35041467
[TBL] [Abstract][Full Text] [Related]
19. Anticancer activity of bisphosphonates in breast cancer.
Gnant M
Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.
Strobl S; Wimmer K; Exner R; Devyatko Y; Bolliger M; Fitzal F; Gnant M
Curr Treat Options Oncol; 2018 Mar; 19(4):18. PubMed ID: 29527635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]